Recognizing Potential Buprenorphine Medication Misuse: Product Packaging Does Not Degrade With Laundering

Area of Science:

• Pharmacology
• Addiction Medicine
• Materials Science

Background:

• Expanded office-based buprenorphine treatment for opioid dependence carries risks of medication misuse and diversion.
• Recurrent early refill requests can signal misuse, necessitating effective clinical recognition strategies.
• Patient claims of medication damage from laundering prompted this investigation into product integrity.

Purpose of the Study:

• To evaluate the impact of laundering on the degradation of buprenorphine-containing medication packaging and contents.
• To determine if laundering is a plausible cause for reported medication damage.
• To inform clinical practice regarding the assessment of patient reports of damaged medication.

Main Methods:

• Assessed four packaging types: foil-wrapped films (Suboxone, Bunavail), blister packs (Zubsolv), and pill bottles.
• Exposed products to two laundering conditions: washing machine (W) and washer/dryer (W+D), compared to a control (C).
• Visually examined packaging and contents by a blinded investigator.

Main Results:

• All packaging and contents remained largely intact across experimental conditions, with only minor cosmetic changes.
• Minimal effects observed: slight wrapper curling (Suboxone), label fading (Zubsolv), foil indentation (Bunavail), and minor tablet nicking (bottle).
• A patient fabricating a laundering story to obtain extra medication highlighted the need for structured treatment and careful evaluation.

Conclusions:

• Laundering is an improbable cause of damage to buprenorphine medications in various packaging formats.
• Patient reports of laundered, damaged buprenorphine products may suggest underlying medication misuse or diversion.
• Clinical practice should consider laundering unlikely as a cause for medication damage in buprenorphine treatment.